Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The investment will accelerate the overall Sarclisa development program
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Acute therapies continue to report strong growth compared to chronic ones.
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Subscribe To Our Newsletter & Stay Updated
